在患有非严重无形性贫血的患者中对单剂环素的反应
Munazza Nabi Awan1, Nighat Shahbaz1, Irsa Hidayat1
1Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|September 12, 2024
概括
单独使用环素A (CSA) 显示出对非严重无质性贫血 (NSAA) 的有希望的有效性,在12个月内观察到显著的整体反应率和生存益处. 这种处理是一种可行的选择,特别是在资源有限的环境中,证明了可以容忍的安全性.
科学领域:
- 血液学 血液学 血液学
- 免疫抑制疗法 免疫抑制疗法
背景情况:
- 非严重的无质性贫血 (NSAA) 需要有效的治疗策略.
- 环素A (CSA) 是一种免疫抑制剂,在血液学疾病中具有潜在的治疗应用.
研究的目的:
- 评估在被诊断患有非严重无塑性贫血 (NSAA) 的患者中单独治疗环素A (CSA) 的有效性.
主要方法:
- 对51名NSAA患者进行了横截面观察性研究.
- 用英国标准血液学委员会 (BCSH) 的标准,在3,6个月和12个月评估了患者的反应.
- 测量结果包括整体存活率 (OS) 和反应率 (完全,部分,整体,无反应).
主要成果:
- 在12个月的整体生存率为86.3%.
- 对CSA单疗的整体反应率 (ORR) 在3个月后为49%,在6个月后为57%,在12个月后为59%.
- 基线血红蛋白和输血依赖与反应率和整体存活率有显著的关联.
结论:
- 单独使用环素A疗法对治疗NSAA具有显著的潜力,这是有利的反应率和生存结果所证明的.
- CSA提供了一种可行的治疗选择,特别是在资源有限的环境中,其安全性概况通常是可以容忍的.
- 观察到与治疗相关的并发症,但并没有否定CSA在这个队列中的整体益处.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...


